The company markets a range of generic pharmaceutical products and has launched two of its first developments into the New Zealand market. These include an analgesic called Maxigesic - the world’s first painkiller to combine paracetamol and ibuprofen - and a novel treatment for allergic rhinitis called Maxiclear Hayfever and Sinus Relief. A third product, Crystacide, is a first aid cream. These products, developed in New Zealand, do not contain pseudoephedrine or codeine.

In December 2013, AFT entered into an exclusive commercialization agreement with Japanese GNI Group for markets outside of China for Etuary (pirfenidone), an idiopathic pulmonary fibrosis (IPF) treatment drug.